Edwards Lifesciences (EW): TAVR Miss Drives PT Cut - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Edwards Lifesciences (EW) PT Lowered to $114 at Stifel, 'Buy' Kept
October 26, 2016 9:20 AM EDTStifel analyst Rick Wise lowered his price target on Edwards Lifesciences (NYSE: EW) to $114.00 (from $122.00) following results but maintained a Buy rating.
Wise commented, "While roughly matching both our projections and company guidance, EW's 3Q sales results -- specifically the critical THVT (Transcatheter Heart Therapy) franchise -- fell short of Street expectations by ~$15M (or 4%). Already down in the aftermarket, EW shares undoubtedly will trade lower tomorrow as well, in our view. Despite this shortfall relative to... More
BTIG Sets New PT of $100 on Edwards Lifesciences (EW); Reports Slight Q3 Miss Amid Lofty Expectations
October 26, 2016 8:57 AM EDTBTIG affirms Edwards Lifesciences (NYSE: EW) with a Buy rating and sets a price target of $110 on the stock following Q3 results.
The firm commented today: Expectations were lofty after multiple beats including Q2 THVs that blew away expectations. We and most others... More
